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Nasopharyngeal carcinoma (NPC) is a radiosensitive and chemosensitive tumour. The aim of this prospective study is to evaluate the
toxicity and efficacy of an outpatient weekly neoadjuvant chemotherapy (NeoCT) plus radiotherapy for advanced NPC. From
November 1998 to August 2001, 90 NPC patients meeting the following criteria were treated: (1) neck node 46cm; (2)
supraclavicular node metastasis; (3) skull base destruction/intracranial invasion plus multiple nodes metastasis; (4) multiple neck nodes
metastasis with one of nodal size 44cm; or (5) elevated serum LDH level. The NeoCT consists of cisplatin 60mgm
 2, alternating
with 5-fluorouracil 2500mgm
 2 plus leucovorin 250mgm
 2 (P–FL) by an outpatient weekly schedule for a total of 10 weeks. Local
radiotherapy X70Gy by conventional fractionation was delivered within 1 week after NeoCT. Patient compliance was rather good.
Grade 3–4 toxicity of NeoCT included leucopaenia (7.8%), anaemia (18.9%), thrombocytopaenia (3.3%), nausea/vomiting (4.4%),
and weight loss (1.1%). Response evaluated after NeoCT showed 73.3% complete response (CR) rate of primary tumour, 71.1% CR
rate of neck nodes, and an overall CR rate of 57.8%. In all, 88 out of 90 patients received rebiopsy of primary tumour and 55 patients
(62.5%) revealed pathological CR. After a median follow-up time of 24 months, one persistent disease and 18 relapses were noted.
The 2-year nasopharynx disease-free, neck disease-free, distant disease-free, overall, and progression-free survival rates are 98.9, 95.9,
80.0, 92.1, and 77.5%, respectively. Preliminary data of the current study show that P–FL NeoCT plus radiotherapy is a low-toxic
regimen with promising results on very advanced NPC patients and merits to be investigated in phase III trials.
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Nasopharyngeal carcinoma (NPC) has several characteristics that
distinguish it from other head and neck malignancies. It is a
geographically endemic, Epstein–Barr virus-associated carcinoma
of epidermoid origin. The NPC cells are poorly differentiated or
undifferentiated with a high incidence of lymphatic and haemato-
logic dissemination, and have greater radiosensitivity. Radio-
therapy is the most effective treatment for NPC because anatomic
constraints make surgery difficult. Although early-stage NPC is
highly radiocurable, the treatment results of locoregionally
advanced NPC have been disappointing.
Combined chemoradiotherapy has been accepted by most
oncologists as the standard treatment of advanced NPC. There is
still great controversy, however, regarding the optimal drugs,
timing, dosage, and duration of chemotherapy. In general, there
are three different ways to incorporate chemotherapy into a
curative course of radiotherapy: before (neoadjuvant), during
(concurrent), and after (adjuvant) radiation therapy. Each mode of
combined therapy has advantages and disadvantages, and has been
extensively investigated during past years. The major flaws of
neoadjuvant chemotherapy (NeoCT) are triggering of accelerated
repopulation and crossresistance during subsequent radiotherapy.
The dose intensity of concurrent chemotherapy that can be
delivered safely during 7–8 weeks radiotherapy is usually lower
than chemotherapy alone. This may compromise its efficacy in
eradication of micrometastasis. Poor compliance and compro-
mised blood supply are the two major problems of adjuvant
chemotherapy. In this prospective study, we designed a novel
schedule of outpatient weekly NeoCT plus radiotherapy for very
advanced NPC.
PATIENTS AND METHODS
In our hospital, all patients with biopsy-proven NPC are subjected
to careful staging and evaluation before treatment. This included
clinical examination of the head and neck region, fibre naso-
pharyngoscopy, computed tomography (CT) scan or magnetic
resonance imaging (MRI) from the skull base to the whole neck,
chest radiography, whole-body bone scan, abdominal sonography,
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lcomplete blood count with differential count, platelet count,
biochemical profile, and EBV serology. Chest CT scan and bone
marrow biopsy were not routine, but selectively performed when
suspicion of lung metastasis in chest radiography and abnormal
blood routine were noted. Cancer stage was defined according to
the American Joint Committee on Cancer (AJCC) 1997 staging
system.
Patient selection for NeoCT
According to our past experience, patients with one of the
following criteria were found to have a high incidence of distant
failure: (1) neck nodal size 46cm; (2) supraclavicular node
metastasis; (3) skull base destruction/intracranial invasion plus
multiple nodes metastasis; (4) multiple neck nodes metastasis with
one of nodal size 44cm, and (5) elevated serum LDH level. From
November 1998 to August 2001, 90 NPC patients meeting our
selection criteria received NeoCT plus radiotherapy after obtaining
informed consent. Other eligibility criteria were: (1) Karnofsky
performance status X60%; (2) white blood cell (WBC) count
43000ml
 1 and platelet count 4100000ml
 1; (3) serum creatinine
level o2.0mgdl
 1; (4) normal liver function with total bilirubin
o2.5mgdl
 1; and (5) no detectable distant metastasis.
Treatment schedule
All patients received a subcutaneous implanted port. Weekly P–FL
NeoCT consisted of cisplatin 60mgm
 2 2-h infusion after
hydration and antiemetics, alternating with 5-fluorouracil (5-FU)
2500mgm
 2 plus leucovorin 250mgm
 2, mixed in 240ml of
normal saline by continuous intravenous infusion for 24h using an
ambulatory pump in an outpatient setting. The NeoCT will be
delayed if Grade 4 toxicity developed, and resumed after recovery.
No dose modification was made and 10 weekly doses were
planned. There were no problems with the subcutaneous port for
chemotherapy administration except for the occurrence of catheter
obstruction in one patient who needed surgical revision.
Radiotherapy was started within 1 week after completion of
NeoCT using a linear accelerator of 6MV photons by the same
technique and fractionation as described previously (Lin and Jan,
1999), except for the incorporation of a 3-D conformal beam for
the last 10–14Gy. The total dose to the primary tumour is 70Gy
for T1-3 and 74Gy for T4 disease. During the initial period of this
trial (before June 1999), two courses of concurrent chemotherapy
comprising 96-h continuous infusion of cisplatin 15mgm
 2day
 1
+5-FU 300mgm
 2day
 1 were planned at the first and fifth weeks
of radiotherapy. Another 10-weekly postradiation adjuvant che-
motherapy (cisplatin 25mgm
 2+5-FU 1250mgm
 2+bleomycin
10mgm
 2+leucovorin 120mgm
 2) was also recommended 2
months after radiotherapy. We discontinued the concurrent and
adjuvant chemotherapy since June 1999 because of poor patient
compliance.
Patient assessments
Chemotherapy toxicity and tumour response were assessed
according to the World Health Organization (WHO) criteria
(Miller et al, 1981). Complete response (CR) was defined as the
complete disappearance of all clinical and radiographic evidence of
disease at the time of objective reevaluation. Partial response (PR)
was defined as a X50% decrease in the sum of the products of the
greatest dimensions of all measurable lesions. Included in the
definition of PR were no new lesions and no progression of any
existing lesions. Stable disease (SD) was defined as a reduction in
tumour size less than PR and an increase in tumour size less than
that defined as progressive disease (PD) or no response. PD was
defined as X25% increase in total tumour size of X1 lesion, or the
appearance of a new lesion.
All patients were routinely assessed by indirect mirror
examination for nasopharynx, palpation of neck nodes, measure-
ment of body weight, complete blood count and platelet count
once a week, or when patients experienced suffering and requested
check-up during the course of chemoradiotherapy. CT scan of
nasopharynx and neck was usually repeated at the ninth to tenth
week for evaluation of tumour response and radiotherapy
planning. Rebiopsy of nasopharynx under fibroscopy was per-
formed before radiotherapy. Liver and renal function tests were
rechecked before and after radiotherapy. After completion of the
whole treatment, patients were followed every 2 months during the
first year, every 3 months for the second and third years, and every
6 months thereafter. CT scan, chest radiograph, abdominal
sonography, whole-body bone scan, blood count, and biochem-
istry tests were routinely performed annually or at the time of
clinical suggestion of tumour relapse.
RESULTS
Patient characteristics
Table 1 lists the pretreatment patient and tumour characteristics
for the 90 patients. Although one of our eligibility criteria was
Karnofsky performance status of 60 or greater, most of our
patients (91.1%) belong to a performance status of 80–100. The
TNM stage distribution of our patients (1997 AJCC T1/T2a/T2b/
Table 1 Patient characteristics
Characteristics
No. of
cases %
Age (years)
Range 24–71
Median 43
Mean 45
Sex
Male 66 73.3
Female 24 26.7
Karnofsky scale
X80% 82 91.1
o80% 8 8.9
Pathology (WHO classification)
Type I 4 4.4
Type II 70 77.8
Type III 16 17.8
T-stage (1997 AJCC)
T1 6 6.7
T2a 2 2.2
T2b 19 21.1
T3 12 13.3
T4 51 56.7
N-stage (1997 AJCC)
N2 56 62.2
N3 34 37.8
Concurrent chemotherapy
Yes 11 12.2
No 79 87.8
Adjuvant chemotherapy
Yes 11 12.2
No 79 87.8
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advanced stage disease.
Patient compliance to P–FL NeoCT
Of 90 patients, 84 finished the planned 10-week P–FL NeoCT
without interruption. Two patients stopped NeoCT prematurely
after seven doses because of their refusal, with complete regression
of their tumour clinically and pathologically. One patient received
two more doses (12 doses) than planned because of a 4-week
interruption by earthquake and personal affair. Another patient
escaped after 8-week NeoCT with clinical complete remission. The
tumour relapsed 11 months later and he received 10-week NeoCT
followed by radiotherapy as schedule. Except for four treatment
interruptions during NeoCT mentioned above, two additional
patients completed the planned NeoCT with a 1-week delay
because of gastrointestinal bleeding and operation for suspected
intra-abdominal metastasis, but proven as benign tumour arising
from the lesser omentum.
Toxicity of P–FL NeoCT
Acute toxicity was mild and well tolerated (Table 2). Some patients
experienced a mild degree of anorexia and weakness during the
NeoCT. Nausea and emesis occurred in 50 of the 90 patients during
their treatment, but was usually mild (only four patients
experienced Grade 3 vomiting). Mucositis was observed in only
three patients of Grade 1–2. In all, 96% of the patients had no
observable hair loss and only 4% patients experienced Grade 1
alopecia. No patients complained of diarrhoea. Body weight loss
was defined as the difference between prechemotherapy body
weight and the nadir body weight during chemotherapy. About
half of the patients experienced body weight loss of mild degree
(only 1.1% belong to Grade 3). There was no liver or renal function
impairment. Haematological toxicity was also mild. Grades 3–4
toxicities occurred in 7.8% of patients for leucopaenia, 3.3% of
patients for thrombocytopaenia, and 18.9% of patients for
anaemia.
Tumour response to P–FL NeoCT
At the end of NeoCT, we observed 52 patients with CR (57.8%), 36
with PR (40.0%), and 2 with SD (2.2%), for an overall response rate
of 97.8% (Table 3). Clinically, CR rates of primary tumour and
neck nodes were 73.3% (66 out of 90) and 71.1% (64 out of 90),
respectively. Figure 1 shows the complete disappearance of
original huge NPC with intracranial invasion after 10-week P–FL
NeoCT. A total of 88 out of 90 patients received rebiopsy before
radiotherapy and pathologically CR was observed in 55 patients
(62.5%).
Toxicity and compliance to subsequent radiotherapy
All except one patient finished radiotherapy X70Gy. One patient
presented with T4N3 tumour that responded poorly to NeoCT. He
refused radiotherapy after 34Gy with stable disease. Most patients
received 70 (31 patients) and 74Gy (54 cases). The average
treatment duration of radiotherapy was 52 days (range 44–84
days). Only five patients completed local radiotherapy more than 9
weeks. Acute toxicity was moderate and manageable (Table 4).
Since we have no gap between NeoCT and subsequent radio-
therapy, chemotherapy-induced bone marrow suppression per-
sisted during the period of the first to third weeks of radiotherapy.
In all, 61% (55 out of 90) of patients encountered the nadir WBC
count o3000ml
 1, usually occurring in the first 3 weeks of
radiotherapy. A total of 52% (47 out of 90) of patients experienced
nadir haemoglobin o8g%. The major toxicity induced by
radiotherapy was mucositis with 52.2% Grade 3 and 26.7% Grade
2. Grades 3 and 2 skin reactions were noted in 26.7 and 48.9% of
the patients, respectively.
Compliance to additional concurrent/adjuvant
chemotherapy
Before June 1999, additional concurrent/adjuvant chemotherapy
was also planned after NeoCT. For the 17 patients intended to be
treated during this period, the compliance to concurrent and/or
adjuvant chemotherapy is poor. At the end of NeoCT, we did not
recommend concurrent chemotherapy because of persistent
leucopaenia o2500ml
 1 in six out of 17 patients. CCRT was
delivered for 11 out of 17 patients, but five patients needed more
delay (41 week) to start CCRT and four patients refused the
Table 2 Acute toxicities of neoadjuvant P–FL chemotherapy
Grade
Toxicity 0123 4
Leucopaenia 21 (23.3%) 30 (33.3%) 32 (35.6%) 7 (7.8%) 0
Anaemia 15 (16.7%) 34 (38.9%) 24 (26.7%) 14 (15.6%) 3 (3.3%)
Thrombocytopaenia 82 (91.1%) 2 (2.2%) 4 (4.4%) 2 (2.2%) 1 (1.1%)
Mucositis 87 (96.7%) 1 (1.1%) 2 (2.2%) 0 0
Nausea/vomiting 40 (44.4%) 33 (36.7%) 13 (14.4%) 4 (4.4%) 0
Weight loss 42 (46.7%) 33 (36.7%) 14 (15.6%) 1 (1.1%) 0
Alopecia 86 (95.6%) 4 (4.4%) 0 0 0
Table 3 Tumour response
Site
Response Nasopharynx Neck Overall
Clinical
CR 66 (73.3%) 64 (71.1%) 52 (57.8%)
PR 23 (25.6%) 24 (26.7%) 36 (40.0%)
SD 1 (1.1%) 2 (2.2%) 2 (2.2%)
Pathological
a
CR 55 (62.5%)
Residual tumour 33 (37.5%)
aA total of 88 out of 90 patients received rebiopsy of nasopharynx after neoadjuvant
chemotherapy before radiotherapy.
CR=complete response, PR=partial response, SD=stable disease.
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was given for 11 out of 17 patients, 2 months after the completion
of radiotherapy. Four of 11 patients had 1–4 weeks interruption
during the adjuvant chemotherapy period and two patients refused
further treatment after 6-week adjuvant chemotherapy. Thus, we
modified our original three-phase chemotherapy to NeoCT+ra-
diotherapy alone for the last 73 patients.
Patterns of failure and survival
The patient who received incomplete radiotherapy at 34Gy was
counted as locoregional failure. The current status of the remain-
ing 89 patients, after a median follow-up of 24 (range 9–42)
months, showed that two patients failed at primary, one patient
failed regionally, one patient failed in neck and distant site, and 14
patients developed distant metastases alone. The 2-year nasophar-
ynx disease-free, neck disease-free, and distant disease-free
survival rates for all patients are 98.9, 95.9, and 80.0%, respectively.
The 2-year overall and progression-free survival rates are 92.1 and
77.5%, respectively (Figure 2).
We also analysed the impact of additional concurrent/adjuvant
chemotherapy on treatment outcome and found no statistically
significant difference in terms of progression-free and overall
survivals. When we evaluated the influence of tumour response
after NeoCT, overall survival (Figure 3A) and progression-free
survival (Figure 3B) were significantly higher in the group who had
a complete response than in the group who had less than a
complete response.
Figure 1 Pretreatment CT scan (A, B) showed a big nasopharyngeal tumour with intracranial invasion in a patient presenting as multiple cranial nerve
palsy. The tumour regressed completely with bony regeneration of the destructed skull base after 10-week neoadjuvant chemotherapy (C, D).
Table 4 Acute toxicities of subsequent radiotherapy
Grade
Toxicity 0123 4
Leucopaenia 9 (10.0%) 26 (28.9%) 41 (45.6%) 14 (15.6%) 0
Anaemia 11 (12.2%) 32 (35.6%) 31 (34.4%) 9 (10.0%) 7 (7.8%)
Thrombocytopaenia 85 (94.4%) 0 3 (3.3%) 1 (1.1%) 1 (1.1%)
Mucositis 0 19 (21.1%) 24 (26.7%) 47 (52.2%) 0
Skin reaction 0 22 (24.4%) 44 (48.9%) 24 (26.7%) 0
Weight loss 22 (24.4%) 34 (37.8%) 33 (36.7%) 1 (1.1%) 0
Nausea/vomiting 84 (93.3%) 6 (6.7%) 0 0 0
Neoadjuvant chemotherapy for advanced NPC
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The late complications that occurred up to the time of this writing
were usually mild. All patients suffered from xerostomia of varying
degrees. A total of 18 patients complained of hearing impairment.
Six patients experienced neck fibrosis of different degrees. Six
patients had trismus and four patients suffered from transient
Lhermitte’s sign. The severe late morbidities (XGrade 3–4)
consist of temporal lobe oedema in one case, trismus 0.2cm in
one case, severe neck fibrosis in four patients, and marked hearing
loss in six patients. Four of these six patients also received
additional cisplatin-based chemotherapy as a salvage for distant
metastases that might contribute to their hearing loss.
DISCUSSION
Treatment failures for advanced NPC in the past have been both
high rates of local recurrence and distant metastasis. As a result of
recent advances in radiation oncology and the combined use of
chemotherapy, the patterns of failure have been predominantly
because of distant metastasis (Huang et al, 1985; Lee et al, 1992;
Chan et al, 1995; Cvitkovic and INCSG, 1996; Lin et al, 1996; Al-
Sarraf et al, 1998; Chua et al, 1998; Cheng et al, 2000; Ma et al,
2001; Wolden et al, 2001). Adding more chemotherapy into
original radiotherapy schedule for patients with high risk of
distant failure is a reasonable and critical approach to enhance
cure rate.
NeoCT for NPC had been tried more than 10 years ago, but
seemed to be abandoned during recent years. Instead, concurrent
chemoradiotherapy (CCRT) with adjuvant chemotherapy has
become popular especially after the Intergroup report (Al-Sarraf
et al, 1998). We agree that concurrent chemotherapy has a good
timing and has some benefits, such as different cell-killing effect,
avoidance of crossresistance, independent toxicity (if careful
selection of the drug), and potentially additive or synergistic
action between radiation and chemotherapy. However, it does not
exclude the potential effect of a different chemotherapy schedule.
To the best of our knowledge, there have been nine phase III
randomised trials to investigate the role of combined chemo-
radiotherapy in NPC so far (Rossi et al, 1988; Chan et al, 1995,
2002; Cvitkovic and INCSG, 1996; Al-Sarraf et al, 1998; Chua et al,
1998; Ma et al, 2001; Chi et al, 2002; Hareyama et al, 2002). Table 5
summarises the results. Unfortunately, most studies showed no
survival benefit. Because of different staging systems, different
prognostic factors, different drugs, and schedules, it is difficult to
compare which one is better. Using concurrent chemotherapy of
cisplatin 100mgm
 2 every 3 weeks during radiotherapy followed
by three monthly cycles of PF (cisplatin+5-FU) postradiation
adjuvant chemotherapy, the Intergoup study of the United States
reported that chemoradiotherapy is superior to radiotherapy alone
(Al-Sarraf et al, 1998). Of 193 patients with 1987 AJCC/UICC stage
III–IV registered, 147 were eligible for analysis. The 3-year
progression-free survival (69 vs 24%, Po0.001) and overall
survival (78 vs 47%, P¼0.005) favoured the chemoradiotherapy
group. Although this is the only randomised trial of positive results
in survival analysis, its wide application to non-American NPC
patients should be considered with caution. First, about 30%
patients of the Intergroup study have WHO type I histology
(keratinising squamous cell carcinoma), but European (Cvitkovic
et al, 1996), Japanese (Hareyama et al, 2002), or Chinese (Chan
et al, 1995, 2002; Chua et al, 1998; Ma et al, 2001; Chi et al, 2002)
series usually contain less than 5% WHO type I patients. Second,
the survival data of radiotherapy alone are unexplainedly low–
24% 3-year progression-free survival rate and 47% 3-year overall
survival rate. The Asian-Oceanian Clinical Oncology Association
(AOCOA) trial (Chua et al, 1998) presented 42% 3-year relapse-
free survival rate and 71% 3-year overall survival for the
radiotherapy alone arm. The Hong Kong trial (Chan et al, 1995)
reported 72% 2-year disease-free survival rate and 80.5% 2-year
overall survival rate for patients receiving radiotherapy alone. The
Italian trial (Rossi et al, 1988) obtained 55.8% 4-year relapse-free
survival rate and 67.3% 4-year overall survival rate. A recent
nonrandomised study from the Memorial Sloan-Kettering Cancer
Center, New York, showed 54% of 3-year progression-free survival
and 71% of 3-year overall survival for radiotherapy alone (Wolden
et al, 2001). A retrospective review from the MD Anderson Cancer
Center (Sanguineti et al, 1997) covering NPC patients who received
radiotherapy alone between 1954 and 1992 also showed a better
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Figure 2 Overall and progression-free survival curves for all 90 patients.
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Figure 3 Comparison of overall survival (A) and progression-free
survival (B) according to tumour response after neoadjuvant chemother-
apy using the Kaplan–Meier estimate and the log-rank test. CR¼complete
response.
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randomised trial.
NeoCT is usually regarded as no benefit at first glance. However,
we reconsider it based on a 10-year experience of combined
chemoradiotherapy in our hospital and a careful literature review.
Our previous study shows that CCRT is better than radiotherapy
alone in local control rate and overall survival for patients with
1992 AJCC stage III–IV diseases. Subgroup analysis for very
advanced disease (such as selection criteria in this study) revealed
no significant difference between CCRT and radiotherapy alone. A
phase II study from the Koo Foundation Sun Yat-Sen Cancer
Center, Taipei, reported excellent results using CCRT plus
adjuvant chemotherapy similar to those of the Intergroup. They
reported 96.6% 3-year disease-free survival for 1997 AJCC stage II
patients, 87.7% for stage III, but only 51.9% for stage IV (Cheng
et al, 2000). The editorial comment (Cooper, 2000) recommended
that stage IV patients need more effective systemic chemotherapy,
such as moving adjuvant therapy to a neoadjuvant position, or
adding NeoCT to Cheng’s regimen, or inserting another drug with
activity in head and neck cancer (e.g. a taxane, mitomycin). A
recent study from the National Taiwan University hospital, Taipei,
reported 70% 5-year overall survival for stage IV patients using
NeoCT of MEPFL (mitomycin, epirubicin, cisplatin, 5-FU, and
leucovorin) followed by radiotherapy (Hong et al, 2001). The 5-
year distant metastasis-free rate of N3a and N3b diseases of AJCC
1997 staging system were 79 and 74%, respectively.
A recent randomised trial from the People’s Republic of China
allocated 456 patients of the Chinese 1992 staging III/IV disease
into 2–3 cycles of PBF (cisplatin, bleomycin, and 5-FU) NeoCT
followed by radiotherapy vs radiotherapy alone (Ma et al, 2001).
Although they failed to demonstrate significant benefit in freedom
from distant metastasis, there is a trend to favour the chemor-
adiotherapy group in terms of 5-year relapse-free survival (59 vs
49%, P¼0.05) and overall survival (63 vs 56%, P¼0.11).
There were several nonrandomised studies showing better
results of NeoCT. In a matched cohort study from the MD
Anderson Cancer Center, significant better 5-year disease-free
survival (6476 vs 4277%, P¼0.015) and overall survival (6976
vs 4877%, P¼0.012) were obtained for the NeoCT group
compared with radiotherapy alone (Geara et al, 1997). The 5-year
cumulative incidence of distant metastasis was 1975% for the
chemoradiotherapy group and 3476% for the radiotherapy alone
group (P¼0.019). A retrospective study from Korea reported
significant better 5-year overall survival (71 vs 59%, P¼0.04) and
freedom from distant metastasis rate (84 vs 66%, P¼0.01),
favouring NeoCT compared with radiotherapy alone (Hong et al,
1999). A larger series containing 618 node-positive NPC patients
from the Prince of Wales Hospital, Hong Kong, compared NeoCT
plus radiotherapy+adjuvant chemotherapy (n¼209) with radio-
therapy alone (n¼409). After a median follow-up of 5.5 years, the
NeoCT group had significantly less local failures than radiotherapy
alone, especially for stage IV patients (Teo et al, 1999).
Before changing policy from CCRT with adjuvant chemotherapy
to NeoCT for very advanced NPC, we also re-evaluate why some
phase III randomised trials could not demonstrate a significant
effect of NeoCT. The possible reasons included a relatively lower
dose of 5-FU (1000mgm
 2day
 1 for 3 days infusion instead of 4
or 5 days in other studies) in the Hong Kong trial (Chan et al,
1995), a relatively lower dose of cisplatin (120–180mgm
 2
person
 1) in the AOCOA trial (Chua et al, 1998), an excess of
chemotherapy-related death and of radiotherapy refusal in the
International Nasopharynx Cancer Study Group (INCSG) trial
(Cvitkovic and INCSG, 1996), or a less advanced stage (Chua et al,
1998). In subgroup analysis for patients with bulky neck lymph
nodes 46cm in the AOCOA trial (Chua et al, 1998), NeoCT
improved 3-year relapse-free survival (63 vs 28%, P¼0.026) and
overall survival (73 vs 37%, P¼0.057). The NeoCT arm had a
significant better disease-free survival but not overall survival in
the INCSG trial (Cvitkovic and INCSG, 1996). If medical care can
be improved to avoid excess treatment-related death and good
communication can be achieved to reduce radiotherapy refusal, we
think that adequate NeoCT followed by radiotherapy may have the
potential to improve survival.
Except for the considerations mentioned above, we also think
that (1) the timing of NeoCT is better than that of concurrent or
adjuvant setting, for example, the best blood supply in the tumour
and the best tolerance in the host; and (2) the dose intensity of
concurrent chemotherapy during 7–8 weeks of radiotherapy is too
Table 5 Literature review of phase III studies in NPC
Authors (published year) Entry criteria Treatment
No. of
cases
Reported
survival (%)
Estimated
a
2-year OS (%)
Rossi et al (1988) 1978 UICC RT 116 67 (4-year OS) 83
Stage II–IV RT+AdjCT 113 59 70
Chi et al (2002) 1988 AJCC/UICC RT 77 60.5 (5-year OS) 80
Stage IV RT+AdjCT 77 54.5 78
Al-Sarraf et al (1998) 1988 AJCC/UICC RT 69 37 (5-year OS*) 58
Stage III–IV CCRT+AdjCT 78 67 82
Chan et al (2002) Ho’s N2-3 or RT 176 69 (2-year RFS)
nodeX4cm CCRT 174 76
Chan et al (1995) Ho’s N3 or RT 40 81 (2-year OS) 81
node X4cm NeoCT+RT+AdjCT 37 80 80
Cvitkovic and INCSG (1996) 1987 UICC RT 168 54 (3-year OS) 60
N2-3 NeoCT+RT 171 60 65
Chua et al (1998) Ho’s T3, N2-3 RT 167 71 (3-year OS) 81
or node X3cm NeoCT+RT 167 78 81
Ma et al (2001) 1992 Chinese RT 228 56 (5-year OS) 82
Stage III–IV NeoCT+RT 228 63 87
Hareyama et al (2002) 1988 AJCC/UICC RT 40 48 (5-year OS) 85
Stage I–IV NeoCT+RT 40 60 88
Current series 1997 AJCC NeoCT+RT 90 92.1 (2-year OS) 92.1
Stage III–IV
*Po0.05.
aFor comparison purposes, we estimated a 2-year overall survival rate from the reported survival curve.
RT=radiotherapy, AdjCT=adjuvant chemotherapy, CCRT=concomitant chemoradiotherapy, NeoCT=neoadjuvant chemotherapy, OS=overall survival, RFS=relapse-free
survival.
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llow to reduce distant failure. At the beginning of this trial, we
initially designed three-phase chemotherapy (neoadjuvant+con-
current+adjuvant) combined with radiotherapy. After the first 17
patients intended to be treated, the compliance to concurrent and/
or adjuvant chemotherapy is poor. Thus, we modified our original
three-phase chemotherapy to NeoCT plus radiotherapy alone.
Under our unique outpatient weekly F–PL NeoCT, we obtained
high CR rate and low toxicity. Clinically and pathologically, CR
rates of the primary tumour were 73.3% (66 out of 90) and 62.5%
(55 out of 88), respectively. Although the median follow-up (24
months) time is short, a high CR rate has reflected low local
recurrence–only 3 of 90 patients with locally advanced tumour
(56.7% 1997 AJCC T4, 13.3% T3, and 21.1% T2b disease) suffered
from recurrent (2) or persistent (1) primary disease. Other exciting
findings of our P–FL NeoCT are rare incidence of mucositis and
nearly no hair loss that made patients more comfortable than any
other chemotherapy regimen. In all, 47% (42 out of 90) patients
had no body weight loss during NeoCT. The outpatient nature of
this treatment and lack of alopecia allowed normal social activity
and saved more cost. The only weak point we are concerned with is
that 10-week NeoCT may be inadequate for eradication of
micrometastasis. So far, 16.7% (15 out of 90) distant failure rate
is rather good for very advanced NPC. Of 64 (31.3%) NPC patients
with the same disease extent who received radiotherapy alone
before September 1998 in our department, 20 developed distant
metastasis within 2 years of follow-up (unpublished data). Of
course, we need a longer time to follow up and evaluate the final
outcomes. Now, we consider adding less toxic adjuvant chemo-
therapy regimen, such as low-dose 5-FU+leucovorin in colo-
rectal cancer. Based on our encouraging results, a phase III
randomised trial to compare NeoCT+radiotherapy+adjuvant
chemotherapy of low-dose 5-FU+leucovorin with CCRT+adjuvant
chemotherapy for very advanced NPC will be initiated in the near
future.
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